Ligand CFO exercises options for 1,736 shares
Ligand Pharmaceuticals’ Chief Financial Officer Octavio Espinoza exercised employee stock options to acquire 1,736 shares of Common Stock on May 27, 2026.
Rhea-AI Filing Summary
Ligand Pharmaceuticals’ Chief Financial Officer Octavio Espinoza exercised employee stock options to acquire 1,736 shares of Common Stock on May 27, 2026. He exercised 972 options at an exercise price of $52.84 per share and 764 options at $63.62 per share. Following these transactions, he directly holds 27,679 Common Shares. The filing also shows 17,407 employee stock options remaining outstanding at a $63.62 exercise price, with expirations in 2032, reflecting routine compensation-related equity activity rather than open‑market buying or selling.
Positive
- None.
Negative
- None.
Insider Trade Summary
1,736 shares exercised/converted
Exercise
4 txns
Insider
Espinoza Octavio
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 972 | $0.00 | $0.00 |
| Exercise | Employee Stock Option (right to buy) | 764 | $0.00 | $0.00 |
| Exercise | Common Stock | 764 | $63.62 | $49K |
| Exercise | Common Stock | 972 | $52.84 | $51K |
Holdings After Transaction:
Employee Stock Option (right to buy) — 17,407 contracts (Direct);
Common Stock — 27,679 shares (Direct)
Footnotes (2)
- F1. The stock option vests as to approximately 55% of the underlying shares in 12 substantially equal monthly installments beginning on January 5, 2025, and approximately 45% of the underlying shares in two substantially equal monthly installments thereafter.
- F2. Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from December 5, 2022, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after December 5, 2022 and the remaining stock options vesting in 42 equal monthly installments thereafter.
Key Figures
Options exercised: 1,736 shares
Exercise price 1: $52.84 per share
Exercise price 2: $63.62 per share
+4 more
7 metrics
Options exercised
1,736 shares
Employee stock option exercises on May 27, 2026
Exercise price 1
$52.84 per share
972 options exercised into Common Stock
Exercise price 2
$63.62 per share
764 options exercised into Common Stock
Shares held after transaction
27,679 shares
Direct Common Stock ownership after exercises
Remaining options
17,407 options
Employee Stock Options at $63.62 exercise price
Option expiration (63.62 grant)
December 13, 2032
Employee Stock Options at $63.62
Option expiration (52.84 grant)
May 5, 2032
Employee Stock Options at $52.84, now fully exercised
Key Terms
Employee Stock Option (right to buy), Exercise or conversion of derivative security, exercise price, vests, +1 more
5 terms
Employee Stock Option (right to buy) financial
"security_title: "Employee Stock Option (right to buy)" in derivative transactions"
Exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
exercise price financial
"conversion_or_exercise_price values of 52.8400 and 63.6200 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vests financial
"The stock option vests as to approximately 55% of the underlying shares..."
installments financial
"in 12 substantially equal monthly installments beginning on January 5, 2025..."
Installments are a series of scheduled partial payments that together cover a larger amount owed or due, like paying for a purchase or loan in weekly or monthly pieces rather than all at once. For investors, installments matter because they change when cash moves between parties, affect a company’s or counterparty’s short-term cash flow and risk of missed payments, and can influence valuation or perceived financial stability much like spreading the cost of a car over monthly payments.
FAQ
What insider transaction did Ligand (LGND) report for CFO Octavio Espinoza?
Ligand reported that CFO Octavio Espinoza exercised employee stock options to acquire 1,736 shares of Common Stock on May 27, 2026. These option exercises are compensation-related events rather than open-market purchases or sales of existing shares.
At what prices did the Ligand (LGND) CFO exercise his stock options?
The CFO exercised 972 options with a $52.84 exercise price and 764 options with a $63.62 exercise price. These amounts reflect the pre-set strike prices of his employee stock options, not the prevailing market price on the exercise date.
How many Ligand (LGND) stock options remain outstanding for the CFO?
The filing shows 17,407 employee stock options remaining outstanding for the CFO at a $63.62 exercise price. These options relate to a grant vesting over time and expiring on December 13, 2032, if not exercised earlier.
AI-generated analysis. How Rhea-AI works. Not financial advice.
